Jefferies reiterates Buy on AbCellera stock, $21 target on VMS therapy

Jefferies maintained a Buy rating and $21 price target for AbCellera Biologics (NASDAQ:ABCL), citing potential in its VMS therapy. The stock is at $11.40, below analyst targets. Q3 revenue rose to $10.6M, beating estimates, with a narrower net loss. ABCL635 showed promising data, and late-stage development is planned for 2027. The company has over $890M in liquidity.

Original reporting
Published Nov 16, 2026, 4:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ABCL
Bullish
high confidence
Mentioned
$ABCL
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ABCLBullishMed
01

Why it matters

The earnings beat and analyst upgrade are likely to attract buying pressure, especially given the company's strong cash position and upcoming late‑stage trial data.

02

Market read

Earnings beat and higher target provide a fresh catalyst for ABCL, making it a short‑term buying opportunity.

03

What to watch

Potential execution risk in late‑stage trials and cash burn could limit upside.

Relevance 7/10Novelty 6/10Timing: post‑market today

Background

AbCellera Biologics (NASDAQ:ABCL) reported Q3 results with revenue of $10.6 M versus $6.21 M consensus and a narrower loss, while Jefferies raised its price target to $21.

Company-level read

Ticker impact

$ABCLBullishHigh confidence
Context

Jefferies reiterated a Buy rating and raised its price target to $21, citing Q3 earnings beat and encouraging late‑stage data for ABCL635.

Expected impact

upward pressure as the market prices in the earnings beat and higher target.

Evidence & confidence

The stock beat revenue and loss expectations, and Jefferies lifted its target, which typically drives buying interest.

Market effects

Positive signal for biotech sector as a peer shows strong data and earnings beat.

North American biotech stocks may see modest gains.

Limited to investors focused on early‑stage biotech pipelines.

Counterpoint

The stock remains highly volatile and the earnings beat was modest; valuation may still be stretched.

Key entities

  • AbCellera Biologics

    Biotech firm developing antibody therapeutics.

  • Jefferies

    Investment bank that reiterated a Buy rating and raised the price target.

Related articles

$ABCLMedAI 8/10

AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results

AbCellera Biologics (ABCL) plans to advance its hot-flash drug, ABCL635, into Phase 3 trials after promising Phase 2 results. The company is modeling dosing and engaging in regulatory discussions with the FDA. ABCL635 showed sleep-score results comparable to Bayer's LYNKUET, according to the company. AbCellera is also developing other candidates, including ABCL992, a longer-acting version of ABCL635.

$ABCLHighAI 9/10

AbCellera (ABCL) Q3 2026 Earnings Call Transcript

AbCellera (ABCL) reported Q3 2026 earnings, highlighting positive results for ABCL635 in treating women's health issues. The drug showed significant reduction in hot flashes and severity of symptoms compared to placebo. The company plans to advance ABCL635 into late-stage development in 2027 and is also exploring its use for cancer treatment-related hot flashes. Additionally, AbCellera announced a new program, ABCL992, and presented Phase I results for ABCL575.

$ABCLHighAI 9/10

AbCellera Q3 2026 slides: ABCL635 data sets new VMS efficacy bar

AbCellera (NASDAQ:ABCL) reported Q3 2026 results, highlighting positive Phase 2 data for ABCL635, its lead program for treating menopausal VMS. The company saw a net loss narrow to $41M and shares rose 5.22% to $12.50. ABCL635 showed significant efficacy in reducing VMS frequency and severity, with 37% of patients achieving complete symptom resolution. AbCellera plans to advance ABCL635 into late-stage trials in 2027 and expand into additional indications.

$ABCLHigh

AbCellera Reports Q3 2026 Business Results

AbCellera Biologics Inc. (ABCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE AbCellera Reports Q3 2026 Business Results 11/9/2026 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars,

$ABCLHighAI 9/10

AbCellera Reports Q3 2026 Business Results

AbCellera (ABCL) reported Q3 2026 results, with revenue up to $10.6M from $9.0M in Q3 2025. Net loss narrowed to $40.8M from $57.1M. The company raised $200M, bringing total liquidity to $890M. Positive Phase 2 data for ABCL635 and Phase 1 data for ABCL575 were announced, along with three new pipeline programs.